Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: A systematic review of randomized controlled trials

Expert Review of Clinical Pharmacology

Volumn 5, Issue 1, 2012, Pages 91-97

  Ang Tiu, Charlene U ^a   Meghrajani, Chandra F ^a   Maano, Clarita C ^a  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

calcineurin inhibitor; pimecrolimus; randomized controlled trials; seborrheic dermatitis; systematic review; treatment

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; HYDROCORTISONE ACETATE; KETOCONAZOLE; METHYLPREDNISOLONE ACEPONATE; METRONIDAZOLE; PIMECROLIMUS; PLACEBO;

ATOPIC DERMATITIS; BURNING SENSATION; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; HUMAN; MAINTENANCE THERAPY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SEBORRHEIC DERMATITIS; SEBUM; SKIN IRRITATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ANIMALS; CALCINEURIN; CHEMISTRY, PHARMACEUTICAL; DERMATITIS, SEBORRHEIC; DERMATOLOGIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 83055170728     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.68     Document Type: Review

References (22)

1. Plewig G, Jansen T. Seborrheic dermatitis. Fitzpatrick's Dermatology in General Medicine (7th Edition). McGraw-Hill, NY, USA, 219-225 (2008).
2. Gupta AK, Chow M. Pimecrolimus: A review. J. Eur. Acad Dermatol. Venerol. 17(5), 493-503 (2003).
3. Warshaw EM, Wohlhuter RJ, Liu A et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J. Am. Acad. Dermatol. 57, 257-264 (2007).
4. Schwartz RA, Janusz CA et al. Seborrheic dermatitis: An overview. Am. Fam. Phys. 74(1), 125-130 (2006).
5. Bikowsky J. Facial seborrheic dermatitis: A report on current status and therapeutic horizons. J. Drugs Dermatol. 8(2), 125-133 (2009).
6. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology 208(2), 89-93 (2004).
7. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol. Online J. 9(3), 13 (2003).
8. Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis. Am. J. Clin. Dermatol. 10(2), 103-118 (2009).
9. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 46(4), 495-504 (2002).
10. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am. J. Clin. Dermatol. 8(3), 157-173 (2007).
11. Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. J. Pharmaceut. 269, 29-35 (2004).
12. Tatlican S, Eren C, Oktay B et al. Experience with repetitive use of pimecrolimus: exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis. J. Dermatol. Treat. 20(3), 1-3 (2009).
13. Sugita T, Tajima M. A new calcineurin inhitibor, pimecrolimus, inhibits the growth of malassezia spp. Antimicrob. Agents Chemother. 50(8), 2897-2898 (2006).
14. Cunha PR. Pimecrolimus cream 1% is effective in seborrheic dermatitis refractory to treatment with topical corticosteroids. Acta Dermatol. Venereol. 86, 69-70 (2006).
15. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp. Clin. Res. 5/6, 191-195 (2005).
16. de Moraes AP, de Arruda EAG, Vitoriano MAV et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J. Eur. Acad. Dermatol. Venerol. 21(5), 596-601 (2007).
17. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J. Am. Acad. Dermatol. 54, 1083-1088 (2006).
18. Firooz A, Solhpour A, Gorouhi F et al. Pimecrolimus cream, 1%, vs. hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: A randomized, investigator-blind, clinical trial. Arch. Dermatol. 142, 1066-1067 (2006).
19. Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J. Dermatol. Treat. 2(1), 4-9 (2009).
20. Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: A randomized clinical study. J. Dermatol. Treat. 20(2), 1-6 (2009).
21. Kim BS, Kim SH, Kim MB et al. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: An open-label clinical study in Korean patients. J. Korean Med. Sci. 22(5), 868-872 (2007).
22. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomized open-label clinical trial. Br. J. Dermatol. 151, 1071-1075 (2004).